GENE ONLINE|News &
Opinion
Blog

Breast Cancer
AstraZeneca and Merck’s HER2-negative Breast Cancer Treatment Wins Yet Another Approval
2022-08-25
Sanofi Abandons SERD Candidate After Second Breast Cancer Clinical Trial Blow
2022-08-18
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
First Targeted Therapy for HER2-Low Breast Cancer Approved by FDA
2022-08-05
Amazon, Fred Hutchinson Begin Human Trial for Cancer Vaccine
2022-07-14
Organon Licenses Biosimilars From Shanghai’s Henlius For $103 Million
2022-06-14
Everest Medicines Secures Breast Cancer Drug Approval in China
2022-06-13
ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics
2022-06-07
Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug
2022-06-06
EU Expands Merck’s Keytruda Use on Breast Cancer
2022-05-25
REVEAL GENOMICS and Dana-Farber Cancer Institute Team Up to Research Breast Cancer
2022-04-29
FDA Grants AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Its Fifth Breakthrough Label
2022-04-28
Alymsys Becomes the Third Biosimilar for Bevacizumab Approved by FDA
2022-04-20
Recent Advances in Breast Cancer Treatments: An Overview
2022-01-15
1 2 3 4
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!